Malin Corporation Plc

Major Shareholding Notification • Apr 11, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9677V

Malin Corporation PLC

11 April 2019

Malin Corporation plc

('Malin' or 'the Company')

Holding(s) in Company

Malin received notification on 11 April, 2019 from Aviva Investors Global Services Limited that as of 10 April, 2019 it holds an aggregate interest in 2,255,045 ordinary shares of €0.001 each, which represents 4.94%* of the issued share capital of the Company. 

*This percentage shareholding is based on a shares in issue figure of 45,681,093 ordinary shares.

Contacts:

Malin

Susan Holburn, Company Secretary

Tel: +353 (0)1 901 5700

info@malinplc.com

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson

Tel: +44 (0)20 3709 5700

malin@consilium-comms.com

Powerscourt (Irish media enquiries)              

Eavan Gannon                                              

Tel: +353 87 236 5973                            

malin@powerscourt-group.com                                                                          

Davy Corporate Finance (Euronext Growth Advisor)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

HOLQFLFFKZFFBBD